We are a biotechnology company developing a novel, revolutionary drug delivery system. Our patented cochleate-based BioralTechnology (Smart Pharmaceuticals) allows biopharmaceutical manufacturers to offer biologically-active compounds with unparalleled convenience, shelf-life, and reduced side effects.

BDSI is applying its drug delivery technology to generic, off-patent injectable drugs and making them patent-protected, oral drugs. BDSI has developed Amphotericin B, the worlds leading antifungal with global sales of $1 billion, into a patent-protected orally-deliverable pharmaceutical ready for clinical trials (Bioral Amphotericin B).

BDSI has demonstrated that the application of the Bioral drug delivery technology to one of its patented, intravenous drugs makes it possible to orally deliver the drug with superior performance in an animal model.

Application of the company's Bioral technology is an effective patent-extension strategy for some pharmaceuticals approaching patent expiration and, as opposed to other technologies, it potentially offers additional clinical benefits such as enhanced effectiveness and reduced side-effects.